Lesley A Inker1, Josef Coresh2, Yingying Sang2, Chi-Yuan Hsu3, Meredith C Foster4, John H Eckfeldt5, Amy B Karger5, Robert G Nelson6, Xun Liu4, Mark Sarnak4, Lawrence J Appel2, Morgan Grams2, Dawei Xie7, Paul L Kimmel8, Harold Feldman7, Vasan Ramachandran9, Andrew S Levey4. 1. William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts; Linker@tuftsmedicalcenter.org. 2. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland. 3. Department of Medicine, University of California-San Francisco, San Francisco, California. 4. William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 6. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona. 7. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 8. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; and. 9. Boston University School of Medicine, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Serum β-trace protein (BTP) and β-2 microglobulin (B2M) are associated with risk of ESRD and death in the general population and in populations at high risk for these outcomes (GP/HR) and those with CKD, but results differ among studies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed an individual patient-level meta-analysis including three GP/HR studies (n=17,903 participants) and three CKD studies (n=5415). We compared associations, risk prediction, and improvement in reclassification of eGFR using BTP (eGFRBTP) and B2M (eGFRB2M) alone and the average (eGFRavg) of eGFRBTP, eGFRB2M, creatinine (eGFRcr), and cystatin C (eGFRcys), to eGFRcr, eGFRcys, and their combination (eGFRcr-cys) for ESRD (2075 events) and death (7275 events). RESULTS: Mean (SD) follow up times for ESRD and mortality for GP/HR and CKD studies were 13 (4), 6.2 (3.2), 14 (5), and 7.5 (3.9) years, respectively. Compared with eGFRcr, eGFRBTP and eGFRB2M improved risk associations and modestly improved prediction for ESRD and death even after adjustment for established risk factors. eGFRavg provided the most consistent improvement in associations and prediction across both outcomes and populations. Assessment of heterogeneity did not yield clinically relevant differences. For ESRD, addition of albuminuria substantially attenuated the improvement in risk prediction and risk classification with novel filtration markers. For mortality, addition of albuminuria did not affect the improvement in risk prediction with the use of novel markers, but lessened improvement in risk classification, especially for the CKD cohort. CONCLUSIONS: These markers do not provide substantial additional prognostic information to eGFRcr and albuminuria, but may be appropriate in circumstances where eGFRcr is not accurate or albuminuria is not available. Educational efforts to increase measurement of albuminuria in clinical practice may be more cost-effective than measurement of BTP and B2M for improving prognostic information.
BACKGROUND AND OBJECTIVES: Serum β-trace protein (BTP) and β-2 microglobulin (B2M) are associated with risk of ESRD and death in the general population and in populations at high risk for these outcomes (GP/HR) and those with CKD, but results differ among studies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed an individual patient-level meta-analysis including three GP/HR studies (n=17,903 participants) and three CKD studies (n=5415). We compared associations, risk prediction, and improvement in reclassification of eGFR using BTP (eGFRBTP) and B2M (eGFRB2M) alone and the average (eGFRavg) of eGFRBTP, eGFRB2M, creatinine (eGFRcr), and cystatin C (eGFRcys), to eGFRcr, eGFRcys, and their combination (eGFRcr-cys) for ESRD (2075 events) and death (7275 events). RESULTS: Mean (SD) follow up times for ESRD and mortality for GP/HR and CKD studies were 13 (4), 6.2 (3.2), 14 (5), and 7.5 (3.9) years, respectively. Compared with eGFRcr, eGFRBTP and eGFRB2M improved risk associations and modestly improved prediction for ESRD and death even after adjustment for established risk factors. eGFRavg provided the most consistent improvement in associations and prediction across both outcomes and populations. Assessment of heterogeneity did not yield clinically relevant differences. For ESRD, addition of albuminuria substantially attenuated the improvement in risk prediction and risk classification with novel filtration markers. For mortality, addition of albuminuria did not affect the improvement in risk prediction with the use of novel markers, but lessened improvement in risk classification, especially for the CKD cohort. CONCLUSIONS: These markers do not provide substantial additional prognostic information to eGFRcr and albuminuria, but may be appropriate in circumstances where eGFRcr is not accurate or albuminuria is not available. Educational efforts to increase measurement of albuminuria in clinical practice may be more cost-effective than measurement of BTP and B2M for improving prognostic information.
Authors: Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor Journal: Am J Kidney Dis Date: 2011-09-22 Impact factor: 8.860
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: John H Eckfeldt; Amy B Karger; W Greg Miller; Gregory P Rynders; Lesley A Inker Journal: Arch Pathol Lab Med Date: 2015-04-17 Impact factor: 5.534
Authors: Meredith C Foster; Lesley A Inker; Chi-Yuan Hsu; John H Eckfeldt; Andrew S Levey; Meda E Pavkov; Bryan D Myers; Peter H Bennett; Paul L Kimmel; Ramachandran S Vasan; Josef Coresh; Robert G Nelson Journal: Am J Kidney Dis Date: 2015-03-12 Impact factor: 8.860
Authors: Xun Liu; Meredith C Foster; Hocine Tighiouart; Amanda H Anderson; Gerald J Beck; Gabriel Contreras; Josef Coresh; John H Eckfeldt; Harold I Feldman; Tom Greene; L Lee Hamm; Jiang He; Edward Horwitz; Julia Lewis; Ana C Ricardo; Haochang Shou; Raymond R Townsend; Matthew R Weir; Lesley A Inker; Andrew S Levey Journal: Am J Kidney Dis Date: 2016-09-20 Impact factor: 8.860
Authors: Meredith C Foster; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; John Eckfeldt; Stephen P Juraschek; Josef Coresh Journal: Am J Kidney Dis Date: 2013-03-19 Impact factor: 8.860
Authors: M C Foster; D E Weiner; A G Bostom; M A Carpenter; L A Inker; P Jarolim; A A Joseph; J W Kusek; T Pesavento; M A Pfeffer; M Rao; S D Solomon; A S Levey Journal: Am J Transplant Date: 2017-03-30 Impact factor: 8.086
Authors: Casey M Rebholz; Lesley A Inker; Yuan Chen; Menglu Liang; Meredith C Foster; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Mark J Sarnak; Chi-Yuan Hsu; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2017-06-23 Impact factor: 8.860
Authors: Hyunju Kim; Bing Yu; Xin Li; Kari E Wong; Eric Boerwinkle; Sara B Seidelmann; Andrew S Levey; Eugene P Rhee; Josef Coresh; Casey M Rebholz Journal: Am J Clin Nutr Date: 2022-07-06 Impact factor: 8.472
Authors: Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas Journal: Front Med (Lausanne) Date: 2017-06-15
Authors: Matthew B Palmer; Amin Abedini; Casey Jackson; Shira Blady; Shatakshee Chatterjee; Katie Marie Sullivan; Raymond R Townsend; Jens Brodbeck; Salem Almaani; Anand Srivastava; Rupali Avasare; Michael J Ross; Amy K Mottl; Christos Argyropoulos; Jonathan Hogan; Katalin Susztak Journal: Kidney Int Rep Date: 2021-02-03
Authors: Mary Hannan; Sajid Ansari; Natalie Meza; Amanda H Anderson; Anand Srivastava; Sushrut Waikar; Jeanne Charleston; Matthew R Weir; Jonathan Taliercio; Edward Horwitz; Milda R Saunders; Katherine Wolfrum; Harold I Feldman; James P Lash; Ana C Ricardo Journal: Clin J Am Soc Nephrol Date: 2020-11-11 Impact factor: 8.237
Authors: Marco Colombo; Helen C Looker; Bassam Farran; Sibylle Hess; Leif Groop; Colin N A Palmer; Mary Julia Brosnan; R Neil Dalton; Max Wong; Charles Turner; Emma Ahlqvist; David Dunger; Felix Agakov; Paul Durrington; Shona Livingstone; John Betteridge; Paul M McKeigue; Helen M Colhoun Journal: Diabetologia Date: 2018-10-05 Impact factor: 10.122